| no |
title |
author |
magazine |
year |
volume |
issue |
page(s) |
type |
| 1 |
A convolutional neural network for fully automated blood SUV determination to facilitate SUR computation in oncological FDG-PET
|
Nikulin, Pavel
|
|
|
48 |
Suppl 1 |
p. 995-1004
|
article
|
| 2 |
A diagnostic strategy for Parkinsonian syndromes using quantitative indices of DAT SPECT and MIBG scintigraphy: an investigation using the classification and regression tree analysis
|
Iwabuchi, Yu
|
|
|
48 |
Suppl 1 |
p. 1833-1841
|
article
|
| 3 |
Aggressive Langerhans cell histiocytosis transformation of T cell acute lymphoblastic leukemia detected on 18F-FDG PET/CT
|
Wang, Jianjie
|
|
|
48 |
Suppl 1 |
p. 642-643
|
article
|
| 4 |
A head-to-head comparison of 68Ga-DOTA-FAPI-04 and 18F-FDG PET/MR in patients with nasopharyngeal carcinoma: a prospective study
|
Qin, Chunxia
|
|
|
48 |
Suppl 1 |
p. 3228-3237
|
article
|
| 5 |
A microdose clinical trial to evaluate [18F]Florastamin as a positron emission tomography imaging agent in patients with prostate cancer
|
Lee, Inki
|
|
|
48 |
Suppl 1 |
p. 95-102
|
article
|
| 6 |
A multicenter comparison of [18F]flortaucipir, [18F]RO948, and [18F]MK6240 tau PET tracers to detect a common target ROI for differential diagnosis
|
Leuzy, Antoine
|
|
|
48 |
Suppl 1 |
p. 2295-2305
|
article
|
| 7 |
An FDG PET/CT metabolic parameter-based nomogram for predicting the early recurrence of hepatocellular carcinoma after liver transplantation
|
Miao, Wenjie
|
|
|
48 |
Suppl 1 |
p. 3656-3665
|
article
|
| 8 |
A proposed index of diffuse bone marrow [18F]-FDG uptake and PET skeletal patterns correlate with myeloma prognostic markers, plasma cell morphology, and response to therapy
|
Paschali, A.
|
|
|
48 |
Suppl 1 |
p. 1487-1497
|
article
|
| 9 |
A simple strategy to reduce the salivary gland and kidney uptake of PSMA-targeting small molecule radiopharmaceuticals
|
Kalidindi, Teja Muralidhar
|
|
|
48 |
Suppl 1 |
p. 2642-2651
|
article
|
| 10 |
Assessing ablation margins of FDG-avid liver tumors during PET/CT-guided thermal ablation procedures: a retrospective study
|
Casadaban, Leigh C.
|
|
|
48 |
Suppl 1 |
p. 2914-2924
|
article
|
| 11 |
Assessing immune organs on 18F-FDG PET/CT imaging for therapy monitoring of immune checkpoint inhibitors: inter-observer variability, prognostic value and evolution during the treatment course of melanoma patients
|
Prigent, Kevin
|
|
|
48 |
Suppl 1 |
p. 2573-2585
|
article
|
| 12 |
Assessment of extra-parenchymal lung involvement in asymptomatic cancer patients with COVID-19 pneumonia detected on 18F-FDG PET-CT studies
|
Wakfie-Corieh, Cristina Gamila
|
|
|
48 |
Suppl 1 |
p. 768-776
|
article
|
| 13 |
Assessment of test-retest reproducibility of [18F]SynVesT-1, a novel radiotracer for PET imaging of synaptic vesicle glycoprotein 2A
|
Li, Songye
|
|
|
48 |
Suppl 1 |
p. 1327-1338
|
article
|
| 14 |
Attenuation correction using deep Learning and integrated UTE/multi-echo Dixon sequence: evaluation in amyloid and tau PET imaging
|
Gong, Kuang
|
|
|
48 |
Suppl 1 |
p. 1351-1361
|
article
|
| 15 |
Augmented deep learning model for improved quantitative accuracy of MR-based PET attenuation correction in PSMA PET-MRI prostate imaging
|
Pozaruk, Andrii
|
|
|
48 |
Suppl 1 |
p. 9-20
|
article
|
| 16 |
Baseline PET/CT imaging parameters for prediction of treatment outcome in Hodgkin and diffuse large B cell lymphoma: a systematic review
|
Frood, R.
|
|
|
48 |
Suppl 1 |
p. 3198-3220
|
article
|
| 17 |
Biodistribution, pharmacokinetics, dosimetry of [68Ga]Ga-DOTA.SA.FAPi, and the head-to-head comparison with [18F]F-FDG PET/CT in patients with various cancers
|
Ballal, Sanjana
|
|
|
48 |
Suppl 1 |
p. 1915-1931
|
article
|
| 18 |
Brain metabolic changes across King’s stages in amyotrophic lateral sclerosis: a 18F-2-fluoro-2-deoxy-d-glucose-positron emission tomography study
|
Canosa, Antonio
|
|
|
48 |
Suppl 1 |
p. 1124-1133
|
article
|
| 19 |
Can 68Ga-PSMA-11 PET/CT predict pathological upgrading of prostate cancer from MRI-targeted biopsy to radical prostatectomy?
|
Yin, Haoli
|
|
|
48 |
Suppl 1 |
p. 3693-3701
|
article
|
| 20 |
Cardiac transthyretin amyloidosis 99mTc-DPD SPECT correlates with strain echocardiography and biomarkers
|
Löfbacka, Viktor
|
|
|
48 |
Suppl 1 |
p. 1822-1832
|
article
|
| 21 |
Cell-free DNA concentration and fragment size fraction correlate with FDG PET/CT-derived parameters in NSCLC patients
|
González de Aledo-Castillo, JM.
|
|
|
48 |
Suppl 1 |
p. 3631-3642
|
article
|
| 22 |
Clinical impact of 18F-FDG-PET among memory clinic patients with uncertain diagnosis
|
Perini, Giulia
|
|
|
48 |
Suppl 1 |
p. 612-622
|
article
|
| 23 |
Clinical impact of follicular oncocytic (Hürthle cell) carcinoma in comparison with corresponding classical follicular thyroid carcinoma
|
Wenter, Vera
|
|
|
48 |
Suppl 1 |
p. 449-460
|
article
|
| 24 |
Clinical insignificance of [18F]PSMA-1007 avid non-specific bone lesions: a retrospective evaluation
|
Arnfield, Evyn G.
|
|
|
48 |
Suppl 1 |
p. 4495-4507
|
article
|
| 25 |
Clinical performance of long axial field of view PET/CT: a head-to-head intra-individual comparison of the Biograph Vision Quadra with the Biograph Vision PET/CT
|
Alberts, Ian
|
|
|
48 |
Suppl 1 |
p. 2395-2404
|
article
|
| 26 |
Clinical translational evaluation of Al18F-NOTA-FAPI for fibroblast activation protein-targeted tumour imaging
|
Wang, Shuailiang
|
|
|
48 |
Suppl 1 |
p. 4259-4271
|
article
|
| 27 |
Clinical utility of perfusion (Q)-single-photon emission computed tomography (SPECT)/CT for diagnosing pulmonary embolus (PE) in COVID-19 patients with a moderate to high pre-test probability of PE
|
Das, Jeeban P.
|
|
|
48 |
Suppl 1 |
p. 794-799
|
article
|
| 28 |
Clinical validation of the novel HDAC6 radiotracer [18F]EKZ-001 in the human brain
|
Koole, Michel
|
|
|
48 |
Suppl 1 |
p. 596-611
|
article
|
| 29 |
Clinical validity of increased cortical uptake of [18F]flortaucipir on PET as a biomarker for Alzheimer’s disease in the context of a structured 5-phase biomarker development framework
|
Wolters, E. E.
|
|
|
48 |
Suppl 1 |
p. 2097-2109
|
article
|
| 30 |
Clinical validity of second-generation tau PET tracers as biomarkers for Alzheimer’s disease in the context of a structured 5-phase development framework
|
Bischof, Gérard N
|
|
|
48 |
Suppl 1 |
p. 2110-2120
|
article
|
| 31 |
Clinical value of negative 68Ga-PSMA PET/CT in the management of biochemical recurrent prostate cancer patients
|
Celli, M
|
|
|
48 |
Suppl 1 |
p. 87-94
|
article
|
| 32 |
[11C]MODAG-001—towards a PET tracer targeting α-synuclein aggregates
|
Kuebler, Laura
|
|
|
48 |
Suppl 1 |
p. 1759-1772
|
article
|
| 33 |
Combined use of 177Lu-DOTATATE and metronomic capecitabine (Lu-X) in FDG-positive gastro-entero-pancreatic neuroendocrine tumors
|
Nicolini, Silvia
|
|
|
48 |
Suppl 1 |
p. 3260-3267
|
article
|
| 34 |
Comparing ATN-T designation by tau PET visual reads, tau PET quantification, and CSF PTau181 across three cohorts
|
Provost, Karine
|
|
|
48 |
Suppl 1 |
p. 2259-2271
|
article
|
| 35 |
Comparison of MRI, [18F]FDG PET/CT, and 99mTc-UBI 29-41 scintigraphy for postoperative spondylodiscitis—a prospective multicenter study
|
Paez, Diana
|
|
|
48 |
Suppl 1 |
p. 1864-1875
|
article
|
| 36 |
Comparison of pretherapeutic osseous tumor volume and standard hematology for prediction of hematotoxicity after PSMA-targeted radioligand therapy
|
Widjaja, Liam
|
|
|
48 |
Suppl 1 |
p. 4077-4088
|
article
|
| 37 |
Comprehensive evaluation of 68Ga-PSMA-11 PET/CT parameters for discriminating pathological characteristics in primary clear-cell renal cell carcinoma
|
Gao, Jie
|
|
|
48 |
Suppl 1 |
p. 561-569
|
article
|
| 38 |
Consensus statements on PSMA PET/CT response assessment criteria in prostate cancer
|
Fanti, Stefano
|
|
|
48 |
Suppl 1 |
p. 469-476
|
article
|
| 39 |
Correction to: Higher thyroid hormone levels and cancer
|
Petranović Ovčariček, Petra
|
|
|
48 |
Suppl 1 |
p. 951-953
|
article
|
| 40 |
Correction to: Machine learning based on clinico-biological features integrated 18F-FDG PET/CT radiomics for distinguishing squamous cell carcinoma from adenocarcinoma of lung
|
Ren, Caiyue
|
|
|
48 |
Suppl 1 |
p. 1696
|
article
|
| 41 |
COVID-19 in the act: incidental 18F-FDG PET/CT findings in asymptomatic patients and those with symptoms not primarily correlated with COVID-19 during the United Kingdom coronavirus lockdown
|
Halsey, Richard
|
|
|
48 |
Suppl 1 |
p. 269-281
|
article
|
| 42 |
CT abnormalities evocative of lung infection are associated with lower 18F-FDG uptake in confirmed COVID-19 patients
|
Bahloul, Achraf
|
|
|
48 |
Suppl 1 |
p. 282-286
|
article
|
| 43 |
Cuneus/precuneus as a central hub for brain functional connectivity of mild cognitive impairment in idiopathic REM sleep behavior patients
|
Mattioli, Pietro
|
|
|
48 |
Suppl 1 |
p. 2834-2845
|
article
|
| 44 |
64Cu-PSMA-BCH: a new radiotracer for delayed PET imaging of prostate cancer
|
Liu, Teli
|
|
|
48 |
Suppl 1 |
p. 4508-4516
|
article
|
| 45 |
Deep learning-assisted ultra-fast/low-dose whole-body PET/CT imaging
|
Sanaat, Amirhossein
|
|
|
48 |
Suppl 1 |
p. 2405-2415
|
article
|
| 46 |
Detection of metastases in newly diagnosed prostate cancer by using 68Ga-PSMA PET/CT and its relationship with modified D’Amico risk classification
|
Simsek, Duygu Has
|
|
|
48 |
Suppl 1 |
p. 1639-1649
|
article
|
| 47 |
Detection of pseudoprogression with [18F]-FDG-PET in a patient with pulmonary large cell neuroendocrine carcinoma who received anti-PD-1 treatment
|
Yamaguchi, Ou
|
|
|
48 |
Suppl 1 |
p. 1268-1270
|
article
|
| 48 |
Development of [89Zr]DFO-elotuzumab for immunoPET imaging of CS1 in multiple myeloma
|
Ghai, Anchal
|
|
|
48 |
Suppl 1 |
p. 1302-1311
|
article
|
| 49 |
Development of [89Zr]ZrDFO-amivantamab bispecific to EGFR and c-MET for PET imaging of triple-negative breast cancer
|
Cavaliere, Alessandra
|
|
|
48 |
Suppl 1 |
p. 383-394
|
article
|
| 50 |
Diagnostic accuracy of FDG-PET/MRI versus pelvic MRI and thoracic and abdominal CT for detecting synchronous distant metastases in rectal cancer patients
|
Queiroz, Marcelo A.
|
|
|
48 |
Suppl 1 |
p. 186-195
|
article
|
| 51 |
Diagnostic performance of preoperative [18F]FDG-PET/CT for lymph node staging in vulvar cancer: a large single-centre study
|
Rufini, Vittoria
|
|
|
48 |
Suppl 1 |
p. 3303-3314
|
article
|
| 52 |
Diagnostic value of [18F]FDG-PET/CT in polymyalgia rheumatica: a systematic review and meta-analysis
|
van der Geest, K. S. M.
|
|
|
48 |
Suppl 1 |
p. 1876-1889
|
article
|
| 53 |
Dose escalation study of targeted alpha therapy with [225Ac]Ac-DOTA-substance P in recurrence glioblastoma – safety and efficacy
|
Królicki, Leszek
|
|
|
48 |
Suppl 1 |
p. 3595-3605
|
article
|
| 54 |
Dosimetry and optimal scan time of [18F]SiTATE-PET/CT in patients with neuroendocrine tumours
|
Beyer, Leonie
|
|
|
48 |
Suppl 1 |
p. 3571-3581
|
article
|
| 55 |
3D voxel-based dosimetry to predict contralateral hypertrophy and an adequate future liver remnant after lobar radioembolization
|
Grisanti, Fabiana
|
|
|
48 |
Suppl 1 |
p. 3048-3057
|
article
|
| 56 |
EANM position paper on article 56 of the Council Directive 2013/59/Euratom (basic safety standards) for nuclear medicine therapy
|
Konijnenberg, Mark
|
|
|
48 |
Suppl 1 |
p. 67-72
|
article
|
| 57 |
Early alkaline phosphatase dynamics as biomarker of survival in metastatic castration-resistant prostate cancer patients treated with radium-223
|
van der Doelen, Maarten J.
|
|
|
48 |
Suppl 1 |
p. 3325-3334
|
article
|
| 58 |
Early preablation rhTSH-stimulated thyroglobulin predicts outcome of differentiated thyroid cancer (DTC) patients
|
Campennì, Alfredo
|
|
|
48 |
Suppl 1 |
p. 2466-2475
|
article
|
| 59 |
Effects of two patient-specific dosing protocols on measurement of myocardial blood flow with 3D 82Rb cardiac PET
|
Arida-Moody, Liliana
|
|
|
48 |
Suppl 1 |
p. 3835-3846
|
article
|
| 60 |
Efficacy of cell proliferation imaging with 4DST PET/CT for predicting the prognosis of patients with esophageal cancer: a comparison study with FDG PET/CT
|
Hotta, Masatoshi
|
|
|
48 |
Suppl 1 |
p. 2615-2623
|
article
|
| 61 |
Efficacy of delayed 18F-FDG hybrid PET/MRI for epileptic focus identification: a prospective cohort study
|
Liu, Fang
|
|
|
48 |
Suppl 1 |
p. 293-301
|
article
|
| 62 |
European Association of Nuclear Medicine October 20-23, 2021 Virtual
|
|
|
|
48 |
Suppl 1 |
p. 1-648
|
article
|
| 63 |
Expert consensus on the safety prevention and control of nuclear medicine diagnosis and treatment during the outbreak of COVID-19 (1st edition): (translated from Chinese version)
|
Lan, Xiaoli
|
|
|
48 |
Suppl 1 |
p. 1134-1143
|
article
|
| 64 |
False positive PSMA PET for tumor remnants in the irradiated prostate and other interpretation pitfalls in a prospective multi-center trial
|
Fendler, Wolfgang P.
|
|
|
48 |
Suppl 1 |
p. 501-508
|
article
|
| 65 |
18F-Boramino acid PET/CT in healthy volunteers and glioma patients
|
Li, Zhu
|
|
|
48 |
Suppl 1 |
p. 3113-3121
|
article
|
| 66 |
18F-DCFPyL PET/CT for primary staging in 160 high-risk prostate cancer patients; metastasis detection rate, influence on clinical management and preliminary results of treatment efficacy
|
Wondergem, M.
|
|
|
48 |
Suppl 1 |
p. 521-531
|
article
|
| 67 |
[18F]DCFPyL PET/CT in detection and localization of recurrent prostate cancer following prostatectomy including low PSA < 0.5 ng/mL
|
Perry, Elisa
|
|
|
48 |
Suppl 1 |
p. 2038-2046
|
article
|
| 68 |
FDG PET/CT parameters and correlations with tumor-absorbed doses in a phase 1 trial of 177Lu-lilotomab satetraxetan for treatment of relapsed non-Hodgkin lymphoma
|
Løndalen, Ayca
|
|
|
48 |
Suppl 1 |
p. 1902-1914
|
article
|
| 69 |
Feasibility of late acquisition [68Ga]Ga-PSMA-11 PET/CT using a long axial field-of-view PET/CT scanner for the diagnosis of recurrent prostate cancer—first clinical experiences
|
Alberts, Ian
|
|
|
48 |
Suppl 1 |
p. 4456-4462
|
article
|
| 70 |
Feasibility of short imaging protocols for [18F]PI-2620 tau-PET in progressive supranuclear palsy
|
Song, Mengmeng
|
|
|
48 |
Suppl 1 |
p. 3872-3885
|
article
|
| 71 |
[18F]-FDG PET/CT in a case of metastatic extrahepatic bile duct cancer from sigmoid carcinoma
|
Liu, Honghong
|
|
|
48 |
Suppl 1 |
p. 1675-1677
|
article
|
| 72 |
2-[18F]FDG PET/CT parameters associated with WHO/ISUP grade in clear cell renal cell carcinoma
|
Zhao, Yanyan
|
|
|
48 |
Suppl 1 |
p. 570-579
|
article
|
| 73 |
18F-FDG PET/CT versus anatomic imaging for evaluating disease extent and clinical trial eligibility in Erdheim-Chester disease: results from 50 patients in a registry study
|
Kirchner, Julian
|
|
|
48 |
Suppl 1 |
p. 1154-1165
|
article
|
| 74 |
(+)-[18F]Flubatine as a novel α4β2 nicotinic acetylcholine receptor PET ligand—results of the first-in-human brain imaging application in patients with β-amyloid PET-confirmed Alzheimer’s disease and healthy controls
|
Tiepolt, Solveig
|
|
|
48 |
Suppl 1 |
p. 731-746
|
article
|
| 75 |
18F-Fluorothymidine PET is an early and superior predictor of progression-free survival following chemoimmunotherapy of diffuse large B cell lymphoma: a multicenter study
|
Minamimoto, Ryogo
|
|
|
48 |
Suppl 1 |
p. 2883-2893
|
article
|
| 76 |
[18F]FMISO PET/CT imaging of hypoxia as a non-invasive biomarker of disease progression and therapy efficacy in a preclinical model of pulmonary fibrosis: comparison with the [18F]FDG PET/CT approach
|
Tanguy, Julie
|
|
|
48 |
Suppl 1 |
p. 3058-3074
|
article
|
| 77 |
Fibroblast imaging of hepatic carcinoma with 68Ga-FAPI-04 PET/CT: a pilot study in patients with suspected hepatic nodules
|
Shi, Ximin
|
|
|
48 |
Suppl 1 |
p. 196-203
|
article
|
| 78 |
First-in-human neuroimaging of soluble epoxide hydrolase using [18F]FNDP PET
|
Coughlin, Jennifer M.
|
|
|
48 |
Suppl 1 |
p. 3122-3128
|
article
|
| 79 |
18F-PSMA-1007 PET/CT for response assessment in patients with metastatic renal cell carcinoma undergoing tyrosine kinase or checkpoint inhibitor therapy: preliminary results
|
Mittlmeier, L. M.
|
|
|
48 |
Suppl 1 |
p. 2031-2037
|
article
|
| 80 |
Fully automated analysis combining [18F]-FET-PET and multiparametric MRI including DSC perfusion and APTw imaging: a promising tool for objective evaluation of glioma progression
|
Paprottka, K. J.
|
|
|
48 |
Suppl 1 |
p. 4445-4455
|
article
|
| 81 |
68Ga-FAPI-PET/CT in patients with various gynecological malignancies
|
Dendl, Katharina
|
|
|
48 |
Suppl 1 |
p. 4089-4100
|
article
|
| 82 |
[68Ga]Ga-DOTA-FAPI-04 PET/CT imaging of benign pulmonary solitary fibrous tumour
|
Liu, Huipan
|
|
|
48 |
Suppl 1 |
p. 2053-2054
|
article
|
| 83 |
[68Ga]Ga-NODAGA-E[(cRGDyK)]2 PET and hyperpolarized [1-13C] pyruvate MRSI (hyperPET) in canine cancer patients: simultaneous imaging of angiogenesis and the Warburg effect
|
Clemmensen, Andreas
|
|
|
48 |
Suppl 1 |
p. 395-405
|
article
|
| 84 |
[68 Ga]Ga-Prostate-Specific Membrane Antigen PET/CT: a novel method for imaging patients with hepatocellular carcinoma
|
Kunikowska, Jolanta
|
|
|
48 |
Suppl 1 |
p. 883-892
|
article
|
| 85 |
[68Ga]Ga-PSMA-HBED-CC PET/CT demonstrates to be superior to ceCT in detecting early treatment response in metastatic clear cell renal cell carcinoma
|
Guglielmo, Priscilla
|
|
|
48 |
Suppl 1 |
p. 3337-3339
|
article
|
| 86 |
Global and segmental absolute stress myocardial blood flow in prediction of cardiac events: [15O] water positron emission tomography study
|
Harjulahti, Esa
|
|
|
48 |
Suppl 1 |
p. 1434-1444
|
article
|
| 87 |
G. Mariani, S. Vidal-Sicart, R.A. Valdes Olmos (Eds): Atlas of Lymphoscintigraphy and Sentinel Node Mapping, Second Edition
|
Sicignano, Marilena
|
|
|
48 |
Suppl 1 |
p. 3345-3346
|
article
|
| 88 |
Grey zone amyloid burden affects memory function: the SCIENCe project
|
Ebenau, J. L.
|
|
|
48 |
Suppl 1 |
p. 747-756
|
article
|
| 89 |
Haris Chrysikopoulos: Errors in Imaging
|
Mansi, Luigi
|
|
|
48 |
Suppl 1 |
p. 1271
|
article
|
| 90 |
Harmonisation of PET/CT contrast recovery performance for brain studies
|
Verwer, E. E.
|
|
|
48 |
Suppl 1 |
p. 2856-2870
|
article
|
| 91 |
Head-to-head comparison of 68Ga-DOTATATE PET/CT and 18F-FDG PET/CT in localizing tumors with ectopic adrenocorticotropic hormone secretion: a prospective study
|
Liu, Qingxing
|
|
|
48 |
Suppl 1 |
p. 4386-4395
|
article
|
| 92 |
Head-to-head comparison of (R)-[11C]verapamil and [18F]MC225 in non-human primates, tracers for measuring P-glycoprotein function
|
García-Varela, Lara
|
|
|
48 |
Suppl 1 |
p. 4307-4317
|
article
|
| 93 |
Head-to-head intra-individual comparison of biodistribution and tumor uptake of 68Ga-FAPI and 18F-FDG PET/CT in cancer patients
|
Giesel, Frederik L.
|
|
|
48 |
Suppl 1 |
p. 4377-4385
|
article
|
| 94 |
HER2-directed antibodies, affibodies and nanobodies as drug-delivery vehicles in breast cancer with a specific focus on radioimmunotherapy and radioimmunoimaging
|
Altunay, Betül
|
|
|
48 |
Suppl 1 |
p. 1371-1389
|
article
|
| 95 |
High dose brachytherapy with non sealed 188Re (rhenium) resin in patients with non-melanoma skin cancers (NMSCs): single center preliminary results.
|
Castellucci, Paolo
|
|
|
48 |
Suppl 1 |
p. 1511-1521
|
article
|
| 96 |
High quality imaging and dosimetry for yttrium-90 (90Y) liver radioembolization using a SiPM-based PET/CT scanner
|
Duan, Heying
|
|
|
48 |
Suppl 1 |
p. 2426-2436
|
article
|
| 97 |
How to better stratify the risk of differentiated thyroid carcinomas: the key role of radioactive iodine therapy, age, and gender
|
Piccardo, Arnoldo
|
|
|
48 |
Suppl 1 |
p. 822-830
|
article
|
| 98 |
Hypermetabolic lymphadenopathy following administration of BNT162b2 mRNA Covid-19 vaccine: incidence assessed by [18F]FDG PET-CT and relevance to study interpretation
|
Cohen, Dan
|
|
|
48 |
Suppl 1 |
p. 1854-1863
|
article
|
| 99 |
Image-based dosimetry for 225Ac-PSMA-I&T therapy using quantitative SPECT
|
Gosewisch, A.
|
|
|
48 |
Suppl 1 |
p. 1260-1261
|
article
|
| 100 |
Image quality and lesion detectability in low-dose pediatric 18F-FDG scans using total-body PET/CT
|
Zhao, Yu-Mo
|
|
|
48 |
Suppl 1 |
p. 3378-3385
|
article
|
| 101 |
Imaging and liquid biopsy in the prediction and evaluation of response to PRRT in neuroendocrine tumors: implications for patient management
|
Roll, Wolfgang
|
|
|
48 |
Suppl 1 |
p. 4016-4027
|
article
|
| 102 |
ImmunoPET imaging of multiple myeloma with [68Ga]Ga-NOTA-Nb1053
|
Wang, Cheng
|
|
|
48 |
Suppl 1 |
p. 2749-2760
|
article
|
| 103 |
ImmunoPET/NIRF/Cerenkov multimodality imaging of ICAM-1 in pancreatic ductal adenocarcinoma
|
Li, Miao
|
|
|
48 |
Suppl 1 |
p. 2737-2748
|
article
|
| 104 |
Impact of EBUS-TBNA in addition to [18F]FDG-PET/CT imaging on target volume definition for radiochemotherapy in stage III NSCLC
|
Guberina, Maja
|
|
|
48 |
Suppl 1 |
p. 2894-2903
|
article
|
| 105 |
Impact of 68Ga-NOTA-MAL-MZHER2 PET imaging in advanced gastric cancer patients and therapeutic response monitoring
|
Zhou, Nina
|
|
|
48 |
Suppl 1 |
p. 161-175
|
article
|
| 106 |
Impact of solitary pulmonary nodule size on qualitative and quantitative assessment using 18F-fluorodeoxyglucose PET/CT: the SPUTNIK trial
|
Weir-McCall, J. R.
|
|
|
48 |
Suppl 1 |
p. 1560-1569
|
article
|
| 107 |
Incidental findings suggestive of COVID-19 in asymptomatic cancer patients undergoing 18F-FDG PET/CT in a low prevalence region
|
Pallardy, Amandine
|
|
|
48 |
Suppl 1 |
p. 287-292
|
article
|
| 108 |
Increased incidence of interstitial pneumonia detected on [18F]-FDG-PET/CT in asymptomatic cancer patients during COVID-19 pandemic in Lombardy: a casualty or COVID-19 infection?
|
Setti, Lucia
|
|
|
48 |
Suppl 1 |
p. 777-785
|
article
|
| 109 |
Indication of retrograde tau spreading along Braak stages and functional connectivity pathways
|
Seemiller, Joseph
|
|
|
48 |
Suppl 1 |
p. 2272-2282
|
article
|
| 110 |
Interim [18F]FDG PET/CT can predict response to anti-PD-1 treatment in metastatic melanoma
|
Sachpekidis, Christos
|
|
|
48 |
Suppl 1 |
p. 1932-1943
|
article
|
| 111 |
Interleukin-2 PET imaging in patients with metastatic melanoma before and during immune checkpoint inhibitor therapy
|
van de Donk, Pim P.
|
|
|
48 |
Suppl 1 |
p. 4369-4376
|
article
|
| 112 |
Intraindividual comparison of [177Lu]Lu-DOTA-EB-TATE and [177Lu]Lu-DOTA-TOC
|
Hänscheid, Heribert
|
|
|
48 |
Suppl 1 |
p. 2566-2572
|
article
|
| 113 |
IntraOmmaya compartmental radioimmunotherapy using 131I-omburtamab—pharmacokinetic modeling to optimize therapeutic index
|
Yerrabelli, Rahul S.
|
|
|
48 |
Suppl 1 |
p. 1166-1177
|
article
|
| 114 |
Just another “Clever Hans”? Neural networks and FDG PET-CT to predict the outcome of patients with breast cancer
|
Weber, Manuel
|
|
|
48 |
Suppl 1 |
p. 3141-3150
|
article
|
| 115 |
Kinetic analysis and optimisation of 18F-rhPSMA-7.3 PET imaging of prostate cancer
|
Malaspina, Simona
|
|
|
48 |
Suppl 1 |
p. 3723-3731
|
article
|
| 116 |
Kinetic metrics of 18F-FDG in normal human organs identified by systematic dynamic total-body positron emission tomography
|
Liu, Guobing
|
|
|
48 |
Suppl 1 |
p. 2363-2372
|
article
|
| 117 |
Long-term outcome of “Sandwich” chemo-PRRT: a novel treatment strategy for metastatic neuroendocrine tumors with both FDG- and SSTR-avid aggressive disease
|
Parghane, Rahul V.
|
|
|
48 |
Suppl 1 |
p. 913-923
|
article
|
| 118 |
177Lu-DOTATATE in older patients with metastatic neuroendocrine tumours: safety, efficacy and health-related quality of life
|
Chen, Luohai
|
|
|
48 |
Suppl 1 |
p. 3582-3594
|
article
|
| 119 |
177Lu-PRRT in advanced gastrointestinal neuroendocrine tumors: 10-year follow-up of the IRST phase II prospective study
|
Paganelli, Giovanni
|
|
|
48 |
Suppl 1 |
p. 152-160
|
article
|
| 120 |
Management impact of 18F-DCFPyL PET/CT in hormone-sensitive prostate cancer patients with biochemical recurrence after definitive treatment: a multicenter retrospective study
|
Meijer, Dennie
|
|
|
48 |
Suppl 1 |
p. 2960-2969
|
article
|
| 121 |
Medical imaging in times of pandemic: focus on the cornerstones of successful imaging
|
Delgado Bolton, Roberto C.
|
|
|
48 |
Suppl 1 |
p. 1724-1725
|
article
|
| 122 |
Multiparametric PET and MRI of myocardial damage after myocardial infarction: correlation of integrin αvβ3 expression and myocardial blood flow
|
Makowski, Marcus R.
|
|
|
48 |
Suppl 1 |
p. 1070-1080
|
article
|
| 123 |
Myocardial creep-induced misalignment artifacts in PET/MR myocardial perfusion imaging
|
von Felten, Elia
|
|
|
48 |
Suppl 1 |
p. 406-413
|
article
|
| 124 |
NEMA NU2-2012 performance measurements of the United Imaging uPMR790: an integrated PET/MR system
|
Chen, Shuguang
|
|
|
48 |
Suppl 1 |
p. 1726-1735
|
article
|
| 125 |
Noninvasive evaluation of tumor immune microenvironment in patients with clear cell renal cell carcinoma using metabolic parameter from preoperative 2-[18F]FDG PET/CT
|
Wu, Caixia
|
|
|
48 |
Suppl 1 |
p. 4054-4066
|
article
|
| 126 |
Non-malignant findings of focal 68Ga-FAPI-04 uptake in pancreas
|
Zhang, Xiao
|
|
|
48 |
Suppl 1 |
p. 2635-2641
|
article
|
| 127 |
Nucleophosmin 1 overexpression correlates with 18F-FDG PET/CT metabolic parameters and improves diagnostic accuracy in patients with lung adenocarcinoma
|
Zhou, Lu-Meng
|
|
|
48 |
Suppl 1 |
p. 904-912
|
article
|
| 128 |
Optimal method for metabolic tumour volume assessment of cervical cancers with inter-observer agreement on [18F]-fluoro-deoxy-glucose positron emission tomography with computed tomography
|
Arshad, Mubarik A.
|
|
|
48 |
Suppl 1 |
p. 2009-2023
|
article
|
| 129 |
Patterns of disease detection using [18F]DCFPyL PET/CT imaging in patients with detectable PSA post prostatectomy being considered for salvage radiotherapy: a prospective trial
|
Koschel, Samantha
|
|
|
48 |
Suppl 1 |
p. 3712-3722
|
article
|
| 130 |
Pelvic lymph-node staging with 18F-DCFPyL PET/CT prior to extended pelvic lymph-node dissection in primary prostate cancer - the SALT trial -
|
Jansen, B. H. E.
|
|
|
48 |
Suppl 1 |
p. 509-520
|
article
|
| 131 |
Performance of [68Ga]Ga-PSMA-11 PET/CT in patients with recurrent prostate cancer after prostatectomy—a multi-centre evaluation of 2533 patients
|
Afshar-Oromieh, Ali
|
|
|
48 |
Suppl 1 |
p. 2925-2934
|
article
|
| 132 |
PET/MRI assessment of lung nodules in primary abdominal malignancies: sensitivity and outcome analysis
|
Biondetti, Pierpaolo
|
|
|
48 |
Suppl 1 |
p. 1976-1986
|
article
|
| 133 |
PET/MRI in prostate cancer: a systematic review and meta-analysis
|
Evangelista, Laura
|
|
|
48 |
Suppl 1 |
p. 859-873
|
article
|
| 134 |
Pharmacokinetic studies of [68 Ga]Ga-PSMA-11 in patients with biochemical recurrence of prostate cancer: detection, differences in temporal distribution and kinetic modelling by tissue type
|
Strauss, Dimitrios S.
|
|
|
48 |
Suppl 1 |
p. 4472-4482
|
article
|
| 135 |
Phase I study to assess safety, biodistribution and radiation dosimetry for 89Zr-girentuximab in patients with renal cell carcinoma
|
Merkx, Robin I. J.
|
|
|
48 |
Suppl 1 |
p. 3277-3285
|
article
|
| 136 |
Physiologic colonic uptake of 18F-FDG on PET/CT is associated with clinical response and gut microbiome composition in patients with advanced non-small cell lung cancer treated with immune checkpoint inhibitors
|
Cvetkovic, Lena
|
|
|
48 |
Suppl 1 |
p. 1550-1559
|
article
|
| 137 |
Preclinical evaluation of [225Ac]Ac-DOTA-TATE for treatment of lung neuroendocrine neoplasms
|
Tafreshi, Narges K.
|
|
|
48 |
Suppl 1 |
p. 3408-3421
|
article
|
| 138 |
Preclinical evaluation of 5-methyltetrahydrofolate-based radioconjugates—new perspectives for folate receptor–targeted radionuclide therapy
|
Guzik, Patrycja
|
|
|
48 |
Suppl 1 |
p. 972-983
|
article
|
| 139 |
Predicting tumor response and prognosis to neoadjuvant chemotherapy in esophageal squamous cell carcinoma patients using PERCIST: a multicenter study in Japan
|
Kaida, Hayato
|
|
|
48 |
Suppl 1 |
p. 3666-3682
|
article
|
| 140 |
Prediction of response and survival after standardized treatment with 7400 MBq 177Lu-PSMA-617 every 4 weeks in patients with metastatic castration-resistant prostate cancer
|
Rasul, Sazan
|
|
|
48 |
Suppl 1 |
p. 1650-1657
|
article
|
| 141 |
Prediction of TERTp-mutation status in IDH-wildtype high-grade gliomas using pre-treatment dynamic [18F]FET PET radiomics
|
Li, Zhicong
|
|
|
48 |
Suppl 1 |
p. 4415-4425
|
article
|
| 142 |
Prevalence of interstitial pneumonia suggestive of COVID-19 at 18F-FDG PET/CT in oncological asymptomatic patients in a high prevalence country during pandemic period: a national multi-centric retrospective study
|
Albano, Domenico
|
|
|
48 |
Suppl 1 |
p. 2871-2882
|
article
|
| 143 |
Prior therapies as prognostic factors of overall survival in metastatic castration-resistant prostate cancer patients treated with [177Lu]Lu-PSMA-617. A WARMTH multicenter study (the 617 trial)
|
Ahmadzadehfar, Hojjat
|
|
|
48 |
Suppl 1 |
p. 113-122
|
article
|
| 144 |
Prognostic implications of dual tracer PET/CT: PSMA ligand and [18F]FDG PET/CT in patients undergoing [177Lu]PSMA radioligand therapy
|
Michalski, Kerstin
|
|
|
48 |
Suppl 1 |
p. 2024-2030
|
article
|
| 145 |
Prognostic Significance of Neutrophil to Lymphocyte Ratio Dynamics in Patients with Hepatocellular Carcinoma Treated with Radioembolization Using Glass Microspheres
|
Li, Xi
|
|
|
48 |
Suppl 1 |
p. 2624-2634
|
article
|
| 146 |
Prognostic value of coronary vascular dysfunction assessed by rubidium-82 PET/CT imaging in patients with resistant hypertension without overt coronary artery disease
|
Gaudieri, Valeria
|
|
|
48 |
Suppl 1 |
p. 3162-3171
|
article
|
| 147 |
Prognostic value of [18F]FDG PET/CT in patients with CNS lymphoma receiving ibrutinib-based therapies
|
Krebs, Simone
|
|
|
48 |
Suppl 1 |
p. 3940-3950
|
article
|
| 148 |
Prognostic value of myocardial perfusion scintigraphy in asymptomatic patients with diabetes mellitus at high cardiovascular risk: 5-year follow-up of the prospective multicenter BARDOT trial
|
Caobelli, Federico
|
|
|
48 |
Suppl 1 |
p. 3512-3521
|
article
|
| 149 |
Promising clinical performance of pretargeted immuno-PET with anti-CEA bispecific antibody and gallium-68-labelled IMP-288 peptide for imaging colorectal cancer metastases: a pilot study
|
Touchefeu, Y.
|
|
|
48 |
Suppl 1 |
p. 874-882
|
article
|
| 150 |
Prospective comparison of 18F-PSMA-1007 PET/CT, whole-body MRI and CT in primary nodal staging of unfavorable intermediate and high-risk prostate cancer
|
Campaña, John
|
|
|
48 |
Suppl 1 |
p. 2670-2671
|
article
|
| 151 |
Prospective comparison of 18F-PSMA-1007 PET/CT, whole-body MRI and CT in primary nodal staging of unfavourable intermediate- and high-risk prostate cancer
|
Malaspina, Simona
|
|
|
48 |
Suppl 1 |
p. 2951-2959
|
article
|
| 152 |
PSMA PET total tumor volume predicts outcome of patients with advanced prostate cancer receiving [177Lu]Lu-PSMA-617 radioligand therapy in a bicentric analysis
|
Seifert, Robert
|
|
|
48 |
Suppl 1 |
p. 1200-1210
|
article
|
| 153 |
PSMA whole-body tumor burden in primary staging and biochemical recurrence of prostate cancer
|
Santos, Allan
|
|
|
48 |
Suppl 1 |
p. 493-500
|
article
|
| 154 |
Pulmonary tumor thrombotic microangiopathy: the role of a lung perfusion SPECT-CT study
|
Antonella, Stefanelli
|
|
|
48 |
Suppl 1 |
p. 3340-3342
|
article
|
| 155 |
Quantification of perivascular inflammation does not provide incremental prognostic value over myocardial perfusion imaging and calcium scoring
|
Bengs, Susan
|
|
|
48 |
Suppl 1 |
p. 1806-1812
|
article
|
| 156 |
Quantitative impact of the first COVID-19 lockdown on nuclear medicine in France: the CORALINE study
|
Vigne, Jonathan
|
|
|
48 |
Suppl 1 |
p. 4331-4338
|
article
|
| 157 |
Radiomic analysis of magnetic resonance fingerprinting in adult brain tumors
|
Dastmalchian, Sara
|
|
|
48 |
Suppl 1 |
p. 683-693
|
article
|
| 158 |
RADTHYR: an open-label, single-arm, prospective multicenter phase II trial of Radium-223 for the treatment of bone metastases from radioactive iodine refractory differentiated thyroid cancer
|
Deandreis, Désirée
|
|
|
48 |
Suppl 1 |
p. 3238-3249
|
article
|
| 159 |
Random survival forest to predict transplant-eligible newly diagnosed multiple myeloma outcome including FDG-PET radiomics: a combined analysis of two independent prospective European trials
|
Jamet, Bastien
|
|
|
48 |
Suppl 1 |
p. 1005-1015
|
article
|
| 160 |
Response and outcome of liver metastases in patients with metastatic castration-resistant prostate cancer (mCRPC) undergoing 177Lu-PSMA-617 radioligand therapy
|
Khreish, Fadi
|
|
|
48 |
Suppl 1 |
p. 103-112
|
article
|
| 161 |
Response to the letter to the Editor by Professors Francesco Giammarile and Stefano Fanti regarding our article “Survey by the ANSM of the imaging protocol, detection rate, and safety of 68Ga-PSMA-11 PET/CT”
|
Chevalme, Yanna-Marina
|
|
|
48 |
Suppl 1 |
p. 2692-2695
|
article
|
| 162 |
Safety and tolerability of 68Ga-NT-20.3, a radiopharmaceutical for targeting neurotensin receptors, in patients with pancreatic ductal adenocarcinoma: the first in-human use
|
Hodolic, Marina
|
|
|
48 |
Suppl 1 |
p. 1229-1234
|
article
|
| 163 |
Sentinel lymph node detection in oral cancer: a within-patient comparison between [99mTc]Tc-tilmanocept and [99mTc]Tc-nanocolloid
|
den Toom, Inne J.
|
|
|
48 |
Suppl 1 |
p. 851-858
|
article
|
| 164 |
Sigma-1 and dopamine D2/D3 receptor occupancy of pridopidine in healthy volunteers and patients with Huntington disease: a [18F] fluspidine and [18F] fallypride PET study
|
Grachev, Igor D.
|
|
|
48 |
Suppl 1 |
p. 1103-1115
|
article
|
| 165 |
Spatially constrained kinetic modeling with dual reference tissues improves 18F-flortaucipir PET in studies of Alzheimer disease
|
Zhou, Yun
|
|
|
48 |
Suppl 1 |
p. 3172-3186
|
article
|
| 166 |
Specific and non-specific binding of a tracer for the translocator-specific protein in schizophrenia: an [11C]-PBR28 blocking study
|
Marques, Tiago Reis
|
|
|
48 |
Suppl 1 |
p. 3530-3539
|
article
|
| 167 |
State-of-the-art of FAPI-PET imaging: a systematic review and meta-analysis
|
Sollini, Martina
|
|
|
48 |
Suppl 1 |
p. 4396-4414
|
article
|
| 168 |
Stereotactic radiotherapy to oligoprogressive lesions detected with 68Ga-PSMA-PET/CT in castration-resistant prostate cancer patients
|
Onal, Cem
|
|
|
48 |
Suppl 1 |
p. 3683-3692
|
article
|
| 169 |
Structural and functional radiomics for lung cancer
|
Wu, Guangyao
|
|
|
48 |
Suppl 1 |
p. 3961-3974
|
article
|
| 170 |
Survey by the French Medicine Agency (ANSM) of the imaging protocol, detection rate, and safety of 68Ga-PSMA-11 PET/CT in the biochemical recurrence of prostate cancer in case of negative or equivocal 18F-fluorocholine PET/CT: 1084 examinations
|
Chevalme, Yanna-Marina
|
|
|
48 |
Suppl 1 |
p. 2935-2950
|
article
|
| 171 |
Synthesis, preclinical evaluation, and a pilot clinical imaging study of [18F]AlF-NOTA-JR11 for neuroendocrine neoplasms compared with [68Ga]Ga-DOTA-TATE
|
Xie, Qing
|
|
|
48 |
Suppl 1 |
p. 3129-3140
|
article
|
| 172 |
Synthesis, radiolabeling, and pre-clinical evaluation of [44Sc]Sc-AAZTA conjugate PSMA inhibitor, a new tracer for high-efficiency imaging of prostate cancer
|
Ghiani, S.
|
|
|
48 |
Suppl 1 |
p. 2351-2362
|
article
|
| 173 |
Targeting fibroblast activation protein in newly diagnosed squamous cell carcinoma of the oral cavity – initial experience and comparison to [18F]FDG PET/CT and MRI
|
Linz, Christian
|
|
|
48 |
Suppl 1 |
p. 3951-3960
|
article
|
| 174 |
The cerebral network of COVID-19-related encephalopathy: a longitudinal voxel-based 18F-FDG-PET study
|
Kas, Aurélie
|
|
|
48 |
Suppl 1 |
p. 2543-2557
|
article
|
| 175 |
The heterogeneity of lung perfusion patterns in SPECT/CT during COVID-19: not only embolism
|
Monaco, Lavinia
|
|
|
48 |
Suppl 1 |
p. 3020-3021
|
article
|
| 176 |
The impact of demographic, clinical, genetic, and imaging variables on tau PET status
|
Ossenkoppele, Rik
|
|
|
48 |
Suppl 1 |
p. 2245-2258
|
article
|
| 177 |
Theranostic implications of molecular imaging phenotype of well-differentiated pulmonary carcinoid based on 68Ga-DOTATATE PET/CT and 18F-FDG PET/CT
|
Zidan, Lamiaa
|
|
|
48 |
Suppl 1 |
p. 204-216
|
article
|
| 178 |
Therapy-related myeloid neoplasm after peptide receptor radionuclide therapy (PRRT) in 1631 patients from our 20 years of experiences: prognostic parameters and overall survival
|
Chantadisai, M.
|
|
|
48 |
Suppl 1 |
p. 1390-1398
|
article
|
| 179 |
The role of 18F-FAZA PET/CT in detecting lymph node metastases in renal cell carcinoma patients: a prospective pilot trial
|
Capitanio, Umberto
|
|
|
48 |
Suppl 1 |
p. 554-560
|
article
|
| 180 |
The strategic biomarker roadmap for the validation of Alzheimer’s diagnostic biomarkers: methodological update
|
Boccardi, Marina
|
|
|
48 |
Suppl 1 |
p. 2070-2085
|
article
|
| 181 |
The use of a visual 4-point scoring scale improves the yield of 18F-FDG PET-CT imaging in the diagnosis of renal and hepatic cyst infection in patients with autosomal dominant polycystic kidney disease
|
Neuville, Marie F.
|
|
|
48 |
Suppl 1 |
p. 254-259
|
article
|
| 182 |
The use of 18F-FDG PET/CT to guide management of adrenal histoplasmosis over time
|
Parisien-La Salle, S.
|
|
|
48 |
Suppl 1 |
p. 1250-1251
|
article
|
| 183 |
The validation status of blood biomarkers of amyloid and phospho-tau assessed with the 5-phase development framework for AD biomarkers
|
Ashton, N. J.
|
|
|
48 |
Suppl 1 |
p. 2140-2156
|
article
|
| 184 |
The value of 18F-FDG PET/CT for predicting or monitoring immunotherapy response in patients with metastatic melanoma: a systematic review and meta-analysis
|
Ayati, Narjess
|
|
|
48 |
Suppl 1 |
p. 428-448
|
article
|
| 185 |
The value of 18F-FDG PET/CT for the diagnosis of device-related infections in patients with a left ventricular assist device: a systematic review and meta-analysis
|
ten Hove, D.
|
|
|
48 |
Suppl 1 |
p. 241-253
|
article
|
| 186 |
Thyroglobulin doubling time offers a better threshold than thyroglobulin level for selecting optimal candidates to undergo localizing [18F]FDG PET/CT in non-iodine avid differentiated thyroid carcinoma
|
Albano, Domenico
|
|
|
48 |
Suppl 1 |
p. 461-468
|
article
|
| 187 |
Total-body dynamic PET/CT of micro-metastatic lymph node in a patient with lung cancer
|
Fu, Fangfang
|
|
|
48 |
Suppl 1 |
p. 1678-1679
|
article
|
| 188 |
Total-body PET/CT using half-dose FDG and compared with conventional PET/CT using full-dose FDG in lung cancer
|
Tan, Hui
|
|
|
48 |
Suppl 1 |
p. 1966-1975
|
article
|
| 189 |
Total metabolic tumor volume and spleen metabolism on baseline [18F]-FDG PET/CT as independent prognostic biomarkers of recurrence in resected breast cancer
|
Seban, Romain-David
|
|
|
48 |
Suppl 1 |
p. 3560-3570
|
article
|
| 190 |
To what extent has the reorganization of nuclear medicine activities during the COVID-19 pandemic fulfilled medical ethics?
|
Gonzalez, Sandra
|
|
|
48 |
Suppl 1 |
p. 3-5
|
article
|
| 191 |
Transpathology: molecular imaging-based pathology
|
Tian, Mei
|
|
|
48 |
Suppl 1 |
p. 2338-2350
|
article
|
| 192 |
Transport-driven engineering of liposomes for delivery of α-particle radiotherapy to solid tumors: effect on inhibition of tumor progression and onset delay of spontaneous metastases
|
Prasad, Aprameya
|
|
|
48 |
Suppl 1 |
p. 4246-4258
|
article
|
| 193 |
True ultra-low-dose amyloid PET/MRI enhanced with deep learning for clinical interpretation
|
Chen, Kevin T.
|
|
|
48 |
Suppl 1 |
p. 2416-2425
|
article
|
| 194 |
Tumour blood flow for prediction of human prostate cancer aggressiveness: a study with Rubidium-82 PET, MRI and Na+/K+-ATPase-density
|
Jochumsen, Mads Ryø
|
|
|
48 |
Suppl 1 |
p. 532-542
|
article
|
| 195 |
Uncovering the invisible—prevalence, characteristics, and radiomics feature–based detection of visually undetectable intraprostatic tumor lesions in 68GaPSMA-11 PET images of patients with primary prostate cancer
|
Zamboglou, Constantinos
|
|
|
48 |
Suppl 1 |
p. 1987-1997
|
article
|
| 196 |
Validation of FDG-PET datasets of normal controls for the extraction of SPM-based brain metabolism maps
|
Caminiti, Silvia Paola
|
|
|
48 |
Suppl 1 |
p. 2486-2499
|
article
|
| 197 |
Value of [68Ga]Ga-FAPI-04 imaging in the diagnosis of renal fibrosis
|
Zhou, Yue
|
|
|
48 |
Suppl 1 |
p. 3493-3501
|
article
|
| 198 |
Visual assessment of [18F]flutemetamol PET images can detect early amyloid pathology and grade its extent
|
Collij, Lyduine E.
|
|
|
48 |
Suppl 1 |
p. 2169-2182
|
article
|
| 199 |
Visual interpretation of [18F]Florbetaben PET supported by deep learning–based estimation of amyloid burden
|
Kim, Ji-Young
|
|
|
48 |
Suppl 1 |
p. 1116-1123
|
article
|
| 200 |
Weakly supervised deep learning for determining the prognostic value of 18F-FDG PET/CT in extranodal natural killer/T cell lymphoma, nasal type
|
Guo, Rui
|
|
|
48 |
Suppl 1 |
p. 3151-3161
|
article
|
| 201 |
What’s behind 68Ga-PSMA-11 uptake in primary prostate cancer PET? Investigation of histopathological parameters and immunohistochemical PSMA expression patterns
|
Rüschoff, Jan H.
|
|
|
48 |
Suppl 1 |
p. 4042-4053
|
article
|
| 202 |
Whole-body voxel-based internal dosimetry using deep learning
|
Akhavanallaf, Azadeh
|
|
|
48 |
Suppl 1 |
p. 670-682
|
article
|
Journal description